Market of liquid biopsies for human genome extraction expected to reach USD 11 billion by 2022
Recent researches on human genome have proved that the detection of irregularities or errors in human genome may revolutionize the way diseases are diagnosed presently, designing of drugs and even the methodology of practice of medicine. For instance, a sequencing technique has changed the methods of screening of fetuses for Down’s syndrome, from an invasive test to one where irregularities in fetal DNA can be recognized from blood drawn from the mother. These kinds of techniques are now expanding to cover other disease areas; the most promising one is treatment of certain types of cancers. Blood tests for diagnosis of genetic changes leading to formation of cancerous tumors could allow doctors to discover more quickly when drugs are no longer effective. It is speculated that the market of such liquid biopsies may reach USD 11 billion by 2022. According to a research firm Research and Markets, Illumina, based in San Diego controlled 70% of the market worth USD 3.3 billion in 2015. Based on the demand of its customers, Illumina may expand to include medical practitioners and its market could grow around USD 12-20 billion by 2020.
